Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-16 4:00 pm Sale | 2024-02-14 | 13D | Theseus Pharmaceuticals, Inc. THRX | TANG CAPITAL PARTNERS LP | 100 100.000% | -3,254,926 (-100.00%) | Filing History |
| 2024-02-13 12:36 pm Sale | 2023-12-31 | 13G | Theseus Pharmaceuticals, Inc. THRX | Frazier Life Sciences Public Fund, L.P. | 0 0.000% | -2,248,194 (Position Closed) | Filing History |
| 2024-01-12 06:02 am Unchanged | 2024-01-09 | 13D | Theseus Pharmaceuticals, Inc. THRX | TANG CAPITAL PARTNERS LP | 3,255,026 7.300% | 0 (Unchanged) | Filing History |
| 2023-12-28 06:00 am Purchase | 2023-12-22 | 13D | Theseus Pharmaceuticals, Inc. THRX | TANG CAPITAL PARTNERS LP | 3,255,026 7.300% | 153,420 (+4.95%) | Filing History |
| 2023-12-27 4:43 pm Unchanged | 2023-12-22 | 13D | Theseus Pharmaceuticals, Inc. THRX | ORBIMED ADVISORS LLC | 17,713,600 40.100% | 0 (Unchanged) | Filing History |
| 2023-11-24 4:28 pm Unchanged | 2023-11-22 | 13D | Theseus Pharmaceuticals, Inc. THRX | ORBIMED ADVISORS LLC | 17,713,600 40.100% | 0 (Unchanged) | Filing History |
| 2023-11-24 4:23 pm Unchanged | 2023-11-22 | 13D | Theseus Pharmaceuticals, Inc. THRX | Foresite Capital Fund V L.P. | 5,494,621 12.400% | 0 (Unchanged) | Filing History |
| 2023-11-24 1:49 pm Purchase | 2023-11-14 | 13D | Theseus Pharmaceuticals, Inc. THRX | TANG CAPITAL PARTNERS LP | 3,101,606 7.000% | 3,101,606 (New Position) | Filing History |
| 2023-08-10 08:19 am Sale | 2023-08-09 | 13G | Theseus Pharmaceuticals, Inc. THRX | FMR LLC | 1,194 0.002% | -2,497,161 (-99.95%) | Filing History |
| 2023-07-19 4:12 pm Purchase | 2023-07-17 | 13D | Theseus Pharmaceuticals, Inc. THRX | ORBIMED ADVISORS LLC | 17,713,600 40.700% | 479,932 (+2.78%) | Filing History |
| 2023-07-19 2:41 pm Purchase | 2023-03-09 | 13D | Theseus Pharmaceuticals, Inc. THRX | Foresite Capital Fund V L.P. | 5,494,621 12.600% | 700,000 (+14.60%) | Filing History |
| 2023-03-14 4:19 pm Purchase | 2023-03-09 | 13D | Theseus Pharmaceuticals, Inc. THRX | ORBIMED ADVISORS LLC | 17,233,668 39.600% | 395,000 (+2.35%) | Filing History |
| 2023-02-09 12:39 pm Sale | 2023-02-09 | 13G | Theseus Pharmaceuticals, Inc. THRX | FMR LLC | 2,498,355 6.453% | -694,308 (-21.75%) | Filing History |
| 2023-01-23 12:17 pm Purchase | 2023-01-13 | 13G | Theseus Pharmaceuticals, Inc. THRX | Frazier Life Sciences Public Fund, L.P. | 2,248,194 5.800% | 2,248,194 (New Position) | Filing History |
| 2023-01-03 4:36 pm Purchase | 2022-12-29 | 13D | Theseus Pharmaceuticals, Inc. THRX | Foresite Capital Fund V L.P. | 4,794,621 12.400% | 500,000 (+11.64%) | Filing History |
| 2022-12-12 08:41 am Sale | 2022-12-09 | 13G | Theseus Pharmaceuticals, Inc. THRX | FMR LLC | 3,192,663 8.246% | -2,256,006 (-41.40%) | Filing History |
| 2022-06-13 4:24 pm Purchase | 2022-06-09 | 13D | Theseus Pharmaceuticals, Inc. THRX | Foresite Capital Fund V L.P. | 4,294,621 11.100% | 613,069 (+16.65%) | Filing History |
| 2022-02-09 10:01 am Purchase | 2022-02-08 | 13G | Theseus Pharmaceuticals, Inc. THRX | FMR LLC | 5,448,669 14.078% | 1,494,953 (+37.81%) | Filing History |
| 2021-11-18 5:10 pm Unchanged | 2021-11-15 | 13D | Theseus Pharmaceuticals, Inc. THRX | ORBIMED ADVISORS LLC | 16,838,668 43.500% | 0 (Unchanged) | Filing History |
| 2021-11-10 12:24 pm Purchase | 2021-11-09 | 13G | Theseus Pharmaceuticals, Inc. THRX | FMR LLC | 3,953,716 10.534% | 3,953,716 (New Position) | Filing History |